Parkinsons Disease With Dementia Clinical Trial
Official title:
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Active, not recruiting |
NCT03608553 -
A Study to Evaluate Temporary Blood Brain Barrier Disruption in Patients With Parkinson's Disease Dementia
|
N/A | |
Recruiting |
NCT04148326 -
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
|
||
Recruiting |
NCT04389437 -
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
|
N/A | |
Active, not recruiting |
NCT02954978 -
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
|
Phase 2 | |
Completed |
NCT00988117 -
The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems
|
Phase 4 |